PE20091348A1 - Derivados de 1,2,4-triazol amino como moduladores de mglur5 - Google Patents
Derivados de 1,2,4-triazol amino como moduladores de mglur5Info
- Publication number
- PE20091348A1 PE20091348A1 PE2008001830A PE2008001830A PE20091348A1 PE 20091348 A1 PE20091348 A1 PE 20091348A1 PE 2008001830 A PE2008001830 A PE 2008001830A PE 2008001830 A PE2008001830 A PE 2008001830A PE 20091348 A1 PE20091348 A1 PE 20091348A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- amino
- triazole
- isoxazol
- mglur5
- Prior art date
Links
- -1 OF 1,2,4-TRIAZOLE AMINO Chemical class 0.000 title abstract 5
- 101150087728 Grm5 gene Proteins 0.000 title 1
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- XIPUIGPNIDKXJU-UHFFFAOYSA-N [CH]1CC1 Chemical class [CH]1CC1 XIPUIGPNIDKXJU-UHFFFAOYSA-N 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REFERIDO A UN COMPUESTO DERIVADO DE 1,2,4-TRIAZOL AMINO DE FORMULA I, DONDE X ES (a), (b), ENTRE OTROS, R1 ES METIL, HALOGENO O CIANO, R2 ES H O FLUORO, R3 Y R4 SON CADA UNO C1-C3 ALQUIL O CICLOPROPIL, R5 ES H, ALQUIL C1-C3 O CICLOPROPIL, Z ES (c), (d), ENTRE OTROS, R6 Y R7 SON CADA UNO H, FLUORO, ALQUIL C1-C3 O ALCOXI C1-C3. SON COMPUESTOS PREFERIDOS: 5-{5-[{[5-(3-CLOROFENIL)ISOXAZOL-3-IL]METIL}(CICLOPROPIL)AMINO]-4-METIL-4H-1,2,4-TRIAZOL-3-IL}PIRIDAZIN-3(2H)-ONA, 6-[4-ETIL-5-(METIL{[5-(3-METILFENIL)ISOXAZOL-3-IL]METIL}AMINO)-4H-1,2,4-TRIAZOL-3-IL]PIRIMIDIN-4(3H)-ONA; 2-METIL-5-[4-METIL-5-(METIL{(1S)-1-[5-(3-METILFENIL)ISOXAZOL-3-IL]ETIL}AMINO)-4H-1,2,4-TRIAZOL-3-IL]PIRIDAZIN-3(2H)-ONA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS mGLUR5, SIENDO UTILES PARA EL TRATAMIENTO DE DEMENCIA SENIL, ENFERMEDAD DE PARKINSON, ESQUIZOFRENIA, RETINOPATIAS, EPILEPSIA, ENTRE OTROS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98295607P | 2007-10-26 | 2007-10-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20091348A1 true PE20091348A1 (es) | 2009-10-04 |
Family
ID=40579779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001830A PE20091348A1 (es) | 2007-10-26 | 2008-10-24 | Derivados de 1,2,4-triazol amino como moduladores de mglur5 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090111821A1 (es) |
| EP (1) | EP2212316A4 (es) |
| JP (1) | JP2011500798A (es) |
| KR (1) | KR20100089091A (es) |
| CN (1) | CN101918399A (es) |
| AR (1) | AR069030A1 (es) |
| AU (1) | AU2008317544A1 (es) |
| BR (1) | BRPI0818679A2 (es) |
| CA (1) | CA2702974A1 (es) |
| CL (1) | CL2008003182A1 (es) |
| CR (1) | CR11391A (es) |
| DO (1) | DOP2010000124A (es) |
| EA (1) | EA201000656A1 (es) |
| IL (1) | IL205289A0 (es) |
| MX (1) | MX2010004362A (es) |
| NI (1) | NI201000072A (es) |
| PE (1) | PE20091348A1 (es) |
| TW (1) | TW200922585A (es) |
| UY (1) | UY31427A1 (es) |
| WO (1) | WO2009054794A1 (es) |
| ZA (1) | ZA201002854B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2438052A1 (en) * | 2009-06-05 | 2012-04-11 | Oslo University Hospital HF | Azole derivatives as wtn pathway inhibitors |
| JP2013544874A (ja) | 2010-12-08 | 2013-12-19 | オスロ ユニヴァーシティー ホスピタル エイチエフ | Ｗｎｔシグナル伝達経路阻害薬としてのトリアゾール誘導体 |
| RU2495687C1 (ru) * | 2012-06-19 | 2013-10-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Северо-Осетинская государственная медицинская академия" Минздравсоцразвития Российской Федерации | Способ лечения больных гастроэзофагеальной рефлюксной болезнью |
| UA113223C2 (xx) * | 2012-08-13 | 2016-12-26 | Арилетинілпіримідини | |
| EP2857387A1 (en) | 2013-10-07 | 2015-04-08 | Boehringer Ingelheim International Gmbh | Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid |
| US9745308B2 (en) | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
| US12435078B2 (en) | 2017-09-18 | 2025-10-07 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9420355D0 (en) * | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| JP4060884B2 (ja) * | 1995-08-28 | 2008-03-12 | 昭和薬品化工株式会社 | 局所麻酔用組成物 |
| US5962536A (en) * | 1998-07-31 | 1999-10-05 | Komer; Gene | Injectable propofol formulations |
| WO2005077345A1 (en) * | 2004-02-03 | 2005-08-25 | Astrazeneca Ab | Compounds for the treatment of gastro-esophageal reflux disease |
| RU2006127575A (ru) * | 2004-02-18 | 2008-03-27 | Астразенека Аб (Se) | Соединение триазола и их применение в качестве антагонистов метаботропного рецептора глутамата |
| MXPA06009019A (es) * | 2004-02-18 | 2007-03-08 | Astrazeneca Ab | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico. |
| AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
| JP2009515997A (ja) * | 2005-11-18 | 2009-04-16 | タケダ サン ディエゴ インコーポレイテッド | グルコキナーゼ活性剤 |
| HRP20110054T1 (hr) * | 2006-03-24 | 2011-02-28 | Eisai R&D Management Co. | Derivat triazolona |
| TW200808777A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGLUR5 modulators III |
| TW200811179A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators VI |
| TW200808800A (en) * | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
| TW200811157A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators I |
| TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
| TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
| TW200821305A (en) * | 2006-10-05 | 2008-05-16 | Astrazeneca Ab | MGluR5 modulators |
| CA2710345C (en) * | 2007-12-21 | 2016-11-15 | Merck Serono S.A. | Triazole oxadiazoles derivatives |
| EP2276746A1 (en) * | 2008-04-10 | 2011-01-26 | Basf Se | Substituted pyridazinylmethyl sulfonamides |
-
2008
- 2008-10-23 WO PCT/SE2008/051197 patent/WO2009054794A1/en not_active Ceased
- 2008-10-23 CA CA2702974A patent/CA2702974A1/en not_active Abandoned
- 2008-10-23 JP JP2010530962A patent/JP2011500798A/ja active Pending
- 2008-10-23 KR KR1020107011336A patent/KR20100089091A/ko not_active Withdrawn
- 2008-10-23 TW TW097140705A patent/TW200922585A/zh unknown
- 2008-10-23 CN CN2008801236495A patent/CN101918399A/zh active Pending
- 2008-10-23 AU AU2008317544A patent/AU2008317544A1/en not_active Abandoned
- 2008-10-23 BR BRPI0818679 patent/BRPI0818679A2/pt not_active Application Discontinuation
- 2008-10-23 EA EA201000656A patent/EA201000656A1/ru unknown
- 2008-10-23 EP EP08842741A patent/EP2212316A4/en not_active Withdrawn
- 2008-10-23 MX MX2010004362A patent/MX2010004362A/es unknown
- 2008-10-24 US US12/258,114 patent/US20090111821A1/en not_active Abandoned
- 2008-10-24 PE PE2008001830A patent/PE20091348A1/es not_active Application Discontinuation
- 2008-10-24 UY UY31427A patent/UY31427A1/es not_active Application Discontinuation
- 2008-10-24 AR ARP080104651A patent/AR069030A1/es unknown
- 2008-10-24 CL CL2008003182A patent/CL2008003182A1/es unknown
-
2010
- 2010-04-22 ZA ZA2010/02854A patent/ZA201002854B/en unknown
- 2010-04-22 IL IL205289A patent/IL205289A0/en unknown
- 2010-04-26 NI NI201000072A patent/NI201000072A/es unknown
- 2010-04-26 CR CR11391A patent/CR11391A/es not_active Application Discontinuation
- 2010-04-26 DO DO2010000124A patent/DOP2010000124A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2212316A4 (en) | 2012-06-27 |
| AU2008317544A1 (en) | 2009-04-30 |
| MX2010004362A (es) | 2010-04-30 |
| DOP2010000124A (es) | 2010-10-15 |
| AR069030A1 (es) | 2009-12-23 |
| BRPI0818679A2 (pt) | 2015-04-14 |
| NI201000072A (es) | 2011-03-24 |
| CL2008003182A1 (es) | 2009-11-27 |
| EA201000656A1 (ru) | 2010-12-30 |
| CA2702974A1 (en) | 2009-04-30 |
| CN101918399A (zh) | 2010-12-15 |
| CR11391A (es) | 2010-08-05 |
| TW200922585A (en) | 2009-06-01 |
| WO2009054794A1 (en) | 2009-04-30 |
| JP2011500798A (ja) | 2011-01-06 |
| UY31427A1 (es) | 2009-05-29 |
| ZA201002854B (en) | 2011-10-26 |
| US20090111821A1 (en) | 2009-04-30 |
| EP2212316A1 (en) | 2010-08-04 |
| KR20100089091A (ko) | 2010-08-11 |
| IL205289A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20091348A1 (es) | Derivados de 1,2,4-triazol amino como moduladores de mglur5 | |
| PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
| PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20110028A1 (es) | Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato | |
| PE20090160A1 (es) | COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20150621A1 (es) | Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3 | |
| PE20060599A1 (es) | DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1 | |
| PE20051047A1 (es) | COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| PE20070187A1 (es) | Moduladores de lxr basados en pirazol | |
| NZ598685A (en) | Heterocylcic derivatives as inhibitors of glutaminyl cyclase | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| PE20091466A1 (es) | Derivados de 4,5-dihidro-oxazol-2-il-amina | |
| PE20131377A1 (es) | Triazina-oxadiazoles | |
| PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
| PE20081467A1 (es) | Compuestos de benzoil amino heterociclico como mediadores de glucoquinasas (glk) | |
| PE20051141A1 (es) | Inhibidores de la polimerasa viral | |
| PE20070021A1 (es) | Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1 | |
| PE20081228A1 (es) | Compuesto heteromonociclico | |
| RU2010125121A (ru) | Биарилзамещенные производные азабициклических алканов | |
| PE20091618A1 (es) | 1,2,4-triazoles trisustituidos | |
| PE20110875A1 (es) | Derivados de isoindol como inhibidores de bace |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |